Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk

Addict Biol. 2014 Mar;19(2):237-239. doi: 10.1111/j.1369-1600.2012.00447.x. Epub 2012 Mar 28.

Abstract

Ibogaine, an alkaloid derived from the African shrub Tabernanthe iboga, has shown promising anti-addictive properties in animals. Anecdotal evidence suggests that ibogaine is also anti-addictive in humans. Thus, it alleviates drug craving and impedes relapse of drug use. Although not licensed as therapeutic drug, and despite evidence that ibogaine may disturb the rhythm of the heart, this alkaloid is currently used as an anti-addiction drug in alternative medicine. Here, we report that therapeutic concentrations of ibogaine reduce currents through human ether-a-go-go-related gene potassium channels. Thereby, we provide a mechanism by which ibogaine may generate life-threatening cardiac arrhythmias.

Keywords: Anti-addiction drug; QT interval prolongation; cardiac arrhythmias; hERG potassium channels; ibogaine; indole alkaloid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Arrhythmias, Cardiac / chemically induced*
  • Behavior, Addictive / drug therapy*
  • Dose-Response Relationship, Drug
  • Ether-A-Go-Go Potassium Channels / antagonists & inhibitors*
  • Excitatory Amino Acid Antagonists / adverse effects
  • Excitatory Amino Acid Antagonists / pharmacology*
  • Female
  • Heart Rate / drug effects
  • Humans
  • Ibogaine / adverse effects
  • Ibogaine / pharmacology*
  • Secondary Prevention

Substances

  • Ether-A-Go-Go Potassium Channels
  • Excitatory Amino Acid Antagonists
  • KCNH1 protein, human
  • Ibogaine